Bausch + Lomb (NYSE:BLCO) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Bausch + Lomb (NYSE:BLCO - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.02, Zacks reports. Bausch + Lomb had a positive return on equity of 3.34% and a negative net margin of 6.62%. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the previous year, the company posted $0.24 EPS. The firm's quarterly revenue was up 9.1% on a year-over-year basis. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Price Performance

Shares of BLCO traded down $0.15 during mid-day trading on Friday, reaching $15.75. The company had a trading volume of 589,705 shares, compared to its average volume of 678,649. The company's 50 day simple moving average is $17.42 and its 200 day simple moving average is $18.13. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The company has a market capitalization of $5.55 billion, a price-to-earnings ratio of -17.30, a P/E/G ratio of 2.17 and a beta of 0.46.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BLCO. Royal Bank of Canada cut their price objective on shares of Bausch + Lomb from $22.00 to $18.00 and set an "outperform" rating for the company in a report on Thursday. Wells Fargo & Company cut their price target on Bausch + Lomb from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Thursday, January 16th. Stifel Nicolaus lowered their price objective on Bausch + Lomb from $19.00 to $18.00 and set a "hold" rating on the stock in a research note on Wednesday, January 29th. HC Wainwright reiterated a "buy" rating and set a $23.00 target price on shares of Bausch + Lomb in a research report on Tuesday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a report on Thursday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $19.83.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.